Copyright
©The Author(s) 2022.
World J Clin Cases. Jul 6, 2022; 10(19): 6580-6586
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6580
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6580
Figure 1 Pulmonary embolism.
A: Pulmonary embolism at the first admission (red arrow); B: Pulmonary embolism in the same part disappeared in November (red arrow).
Figure 2 Immunoadsorption, hormone and cyclophosphamide comprehensive treatment plan.
Background anticoagulant therapy; Rivaroxaban 20 mg/d. Immunoadsorption has five specific times: September 12, 2019, September 14, 2019, September 16, 2019, October 9, 2019, October 11, 2019; Cyclophosphamide has four specific times: November 20, 2019, December 28, 2019, September 2, 2019, September 3, 2019; Intravenous immunoglobulin has five specific times: September 18, 2019, September 19, 2019, September 20, 2019, October 13, 2019, October 14, 2019. MP: Methylprednisolone; IG: Immunoglobulin; CTX: Cyclophosphamide; IA: immunoadsorption.
Figure 3 During the 1 yr follow-up, the trends of antiphospholipid antibodies and lupus anticoagulant.
Figure 4 Changes in lupus anticoagulant values during treatment.
dRVVT: Diluted russell viper venom time; SCT: Sickle cell trait.
- Citation: Song Y, Xiao YZ, Wang C, Du R. Immunoadsorption therapy for Klinefelter syndrome with antiphospholipid syndrome in a patient: A case report. World J Clin Cases 2022; 10(19): 6580-6586
- URL: https://www.wjgnet.com/2307-8960/full/v10/i19/6580.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i19.6580